药物临床试验登记与信息公示平台数据显示,石药集团巨石生物制药有限公司的评价SYS6026单药或联合治疗晚期实体瘤的安全性和耐受性、疗效、PK以及免疫原性的多中心、开放、Ⅰ期临床研究已启动。临床试验登记号为CTR20253603,首次公示信息日期为2025年9月9日。该药物剂型为注射剂,规格为100μg (1.0mL)/瓶,前3次免疫接种分别在D1、D15和D36,间隔3周后,进行第4次免疫接种,...
Source Link药物临床试验登记与信息公示平台数据显示,石药集团巨石生物制药有限公司的评价SYS6026单药或联合治疗晚期实体瘤的安全性和耐受性、疗效、PK以及免疫原性的多中心、开放、Ⅰ期临床研究已启动。临床试验登记号为CTR20253603,首次公示信息日期为2025年9月9日。该药物剂型为注射剂,规格为100μg (1.0mL)/瓶,前3次免疫接种分别在D1、D15和D36,间隔3周后,进行第4次免疫接种,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.